GlassScriptPhysician profile
Richard A Memo
NPI 1710951702
$8,320.47
in general payments reported to CMS, 2019-2025
49 companies · $4,260 in 2025
The $4,260 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $470 · 2021: $821 · 2022: $521 · 2023: $1,127 · 2024: $941 · 2025: $4,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,073 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,073.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,261.39 | 2025 | |
| Dendreon Pharmaceuticals LLC | $573.57 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $550.16 | 2019-2025 | Xtandi, Myrbetriq |
| Dentsply Ih INC. | $371.82 | 2020 | |
| Pfizer INC. | $301.50 | 2021-2025 | |
| Axonics, INC. | $263.57 | 2023-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $247.74 | 2021-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $243.51 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $233.53 | 2023 | Prolaris |
| Sumitomo Pharma America, INC. | $219.22 | 2023-2024 | Orgovyx, Gemtesa |
| Immunitybio, INC. | $206.71 | 2025 | |
| Merck Sharp & Dohme LLC | $180.63 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Calyxo, INC. | $146.12 | 2025 | Cvac Aspiration System |
| Teleflex LLC | $134.12 | 2021 | |
| Novartis Pharmaceuticals Corporation | $103.98 | 2024-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Memo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.